Prevalence of COVID-19 in a French Dependent Care Facility for the Elderly and in a French Long-term Care Unit: Observational Study

Overview

The aim of this study is to evaluate the prevalence of COVID-19 among the residents and geriatric inpatients of the care facilities attached to the Centre Hospitalier Sud Essonne (a general hospital located in Ile-de-France, France), and the factors that are likely to influence this prevalence.

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: May 31, 2021

Detailed Description

Among people exposed to the COVID-19 (SARS-COV-2) pandemic, elderly people are considered as particularly vulnerable, especially those living in nursing homes or hospitalized. Furthermore, facilities / accommodations are registered among the main locations of COVID-19 clusters. These observations have led the French government to establish specific protection measures and survey dependent care facilities for the elderly and long-term care units in the hospital. With these new standards established, a long-term study of all the residents and geriatric inpatients of the care facilities attached to the Centre Hospitalier Sud Essonne (a general hospital located in Ile-de-France, France), can provide additional knowledge on COVID-19.

Interventions

  • Diagnostic Test: Serology testing, RT PCR
    • Periodic testings and testings with characteristic symptoms occur

Clinical Trial Outcome Measures

Primary Measures

  • General prevalence of COVID-19
    • Time Frame: Through the study completion, an average of 12 months
    • measures the prevalence of COVID-19 among the residents and geriatric inpatients, defined as resident and patients with positive serologic or RT-PCR test

Secondary Measures

  • Number of asymptomatic residents/inpatients
    • Time Frame: Through study completion, an average of 12 months
    • no RT-PCR test or negative RT-PCR test and positive serologic test, positive RT PCR and no symptoms.
  • Number of symptomatic residents/inpatients
    • Time Frame: Through study completion, an average of 12 months
    • Positive RT-PCR test or serologic test with symptoms
  • Number of residents/inpatients with severe form of COVID-19 which led to an hospitalization
    • Time Frame: Through study completion, an average of 12 months
    • Positive RT-PCR test or serologic test and hospitalization
  • Number of residents/inpatients infected with COVID-19 and hospitalized in a critical care unit
    • Time Frame: Through study completion, an average of 12 months
    • Positive RT-PCR test or serologic test and hospitalization in critical care unit
  • Number of residents/inpatients infected with COVID-19 and deceased
    • Time Frame: Through study completion, an average of 12 months
    • Positive RT-PCR test or serologic test and deceased
  • Number of residents/inpatients vaccinated against COVID-19
    • Time Frame: Through study completion, an average of 12 months
    • Positive RT-PCR test or serologic test and vaccinated with any authorized vaccine
  • Influencing factors of the prevalence of COVID-19 among residents/inpatients
    • Time Frame: Through study completion, an average of 12 months
    • age sex comorbidities the context of the infection with COVID-19 vaccinated or not

Participating in This Clinical Trial

Inclusion Criteria

  • residents of the dependant care facility for the elderly – inpatients of the long-term care unit – from march, 2020 to december, 2021 Exclusion Criteria:

  • opposition to participate in this study

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Centre Hospitalier Sud Essonne
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Shidasp SIAMI, MD, PhD, Principal Investigator, Centre Hospitalier Sud Essonne
  • Overall Contact(s)
    • Shidasp SIAMI, MD, PhD, 0033 1 60 80 79 40, ssiami@ch-sudessonne.fr

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.